In contrast to the above studies and the current analysis, most studies of HPC families investigating the contribution of protein-truncating BRCA2 mutations to prostate cancer susceptibility have reported null results (Wilkens et al, 1999; Gayther et al, 2000; Sinclair et al, 2000; Agalliu et al, 2007). The gene discussed is BRCA2; the disease is prostate carcinoma.